|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.52 | 89.34 | 104.64 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
114.00
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Audited / UnAudited | UnAudited | UnAudited | UnAudited | UnAudited | Net Sales | 431.10 | 395.42 | 354.19 | 373.70 | Total Expenditure | 395.91 | 364.80 | 331.70 | 346.88 | PBIDT (Excl OI) | 35.19 | 30.62 | 22.49 | 26.82 | Other Income | 0.50 | 0.03 | 4.52 | 1.58 | Operating Profit | 35.70 | 30.66 | 27.01 | 28.40 | Interest | 12.75 | 12.98 | 11.10 | 10.29 | Exceptional Items | -0.58 | 0 | 0 | 2.30 | PBDT | 22.37 | 17.68 | 15.91 | 20.41 | Depreciation | 4.95 | 4.94 | 4.74 | 4.96 | Profit Before Tax | 17.42 | 12.74 | 11.17 | 15.45 | Tax | 5.20 | 4.19 | 3.07 | 2.13 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | 12.22 | 8.55 | 8.10 | 13.32 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | 12.22 | 8.55 | 8.10 | 13.32 | Equity Capital | 75.31 | 75.30 | 75.31 | 75.31 | Face Value (IN RS) | 10 | 10 | 10 | 10 | Reserves | | | | | Calculated EPS | 1.62 | 1.14 | 1.08 | 1.77 | Calculated EPS (Annualised) | 6.49 | 4.54 | 4.30 | 7.07 | No of Public Share Holdings | 3,527,300.00 | 3,527,300.00 | 3,527,300.00 | 3,530,300.00 | % of Public Share Holdings | 46.84 | 46.84 | 46.84 | 46.88 | | | | | | PBIDTM% (Excl OI) | 8.16 | 7.74 | 6.35 | 7.18 | PBIDTM% | 8.28 | 7.75 | 7.63 | 7.60 | PBDTM% | 5.19 | 4.47 | 4.49 | 5.46 | PBTM% | 4.04 | 3.22 | 3.15 | 4.13 | PATM% | 2.83 | 2.16 | 2.29 | 3.56 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|